8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

January 7, 2016

Date of Report (Date of Earliest Event Reported)

VIVEVE MEDICAL, INC.

(Exact Name of Registrant as Specified in Its Charter)

Yukon Territory	1-11388	04-3153858
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

150 Commercial Street

Sunnyvale, California 94086

(Address of Principal Executive Offices)

(408) 530-1900

(Issuer’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02     Results of Operations and Financial Condition

On January 7, 2016, Viveve Medical, Inc. issued a press release to discuss its results of operations for the quarter ended December 31, 2015. The press release is furnished as Exhibit 99.1 and incorporated herein by reference.

The information furnished herewith pursuant to Item 2.02 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.

Item 9.01.     Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Press Release issued January 7, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: January 7, 2016	By:	/s/ Patricia Scheller
		Patricia Scheller, Chief Executive Officer

Exhibit Index

Exhibit No.	Description
99.1	Press Release issued January 7, 2016.

EX-99.1

Exhibit 99.1

Viveve® Announces Fourth Quarter Financial Highlights

SUNNYVALE, California – January 7, 2016 -- Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company focused on women's health, today announced top-line financial results for the quarterly period ended December 31, 2015. The company began its global commercialization effort in the second half of 2015.

Financial Result Highlights

For the quarterly period ended December 31, 2015, total revenue from the sale of 21 Viveve Systems and 216 treatment tips is expected to be approximately $750,000 - nearly a 30% increase over total revenue for the quarterly period ended September 30, 2015.

“We now have a total commercial installed base of 42 Viveve Systems, 33 of which were sold during the last two quarters of 2015. We anticipate an increase in this installed base as we continue to achieve regulatory clearances in additional countries,” said Scott Durbin, Chief Financial Officer of Viveve.

“We believe that our safe, non-invasive and clinically proven treatment for vaginal laxity addresses a large clinical need, as evidenced by the continued growth in the demand for procedures. We believe that the distribution network we have established, with experienced distributors around the world, has begun to establish Viveve as a premier global brand focused on women’s health,” said Patricia Scheller, Chief Executive Officer of Viveve.

Viveve cautions that its anticipated revenue results are preliminary based on the most current information available and are subject to completion of the consolidated financial statements for the fourth quarter of 2015. The company anticipates reporting its fourth quarter and annual 2015 financial results in March 2016.

2015 Company Achievements

● Expanded our commercialization team with the hiring of an experienced industry executive

● Announced a positive interim analysis from the VIVEVE I clinical study

● Research analyst coverage initiated by three firms

● Launched distribution coverage in 46 countries throughout the world

● Achieved regulatory approval in 20 of the 46 countries, which includes Japan under the physician import license pathway

● Completed $18 million in equity financing

About Viveve

Viveve, Inc., the operating subsidiary of Viveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the patented Viveve System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue. The Viveve System treats the condition of vaginal laxity, which is the result of the over-stretching of tissue during childbirth that can result in a decrease in physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to tighten vaginal tissue in a single 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in various countries around the world and is available through physician import license in Japan. It is currently not available for sale in the U.S. For more information, please visit Viveve's website at www.viveve.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are "forward-looking statements" including statements about any of the following: any projections of earnings, revenue, sales, profit margins, or any other financial items; the plans, strategies and objectives of management for growth and future operations or prospects for achieving such plans, and any statements of assumptions underlying any of the foregoing. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Viveve is a registered trademark of Viveve, Inc.

Contact:

Amato and Partners, LLC 
Investor Relations Counsel
90 Park Avenue. 17th Floor
New York, NY 10016
212.430.0360
admin@amatoandpartners.com